Anti-Siglec-7 antibodies and methods of use thereof

US11390680B2 · kind B2 · utility

Assignee

• Alector LLC

Inventors

• Kate Monroe · Berkeley, US
• Helen LAM · Union City, US
• Arnon Rosenthal · Woodside, US
• Seung-Joo Lee · Goyang-si, KR
• Francesca Avogadri-Connors · Lasów Chojnowskich, US
• William MONTEITH · San Francisco, US

Key dates

• Filing date: Feb 14, 2020
• Grant date: Jul 19, 2022
• Expiry date: Feb 14, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.